Bert Vogelstein

Johns Hopkins University

Full Professor(heuristic)

Cancer Genomics and Diagnostics · Cancer Research

h-index255

i10-index603

Publications1,045

Citations370,553

Grants

50 total · 0 active

NIH #5P50CA062924-28

Developmental Research Program

Amount: $124K
Period: 1997-02-28 → 2024-08-31
PIs: 1
Est. capacity / PI: ~0 students

NIH #5P50CA062924-27

Developmental Research Program

Amount: $110K
Period: 1997-02-28 → 2023-08-31
PIs: 1
Est. capacity / PI: ~0 students

NIH #5P50CA062924-26

Developmental Research Program

Amount: $126K
Period: 1997-02-28 → 2023-08-31
PIs: 1
Est. capacity / PI: ~0 students

Student capacity is a rough estimate from remaining award size, split equally among PIs. Actual funding decisions vary.

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

Potential Collaborators

Recent Publications

Last 2 years · showing 20 of 107

Sa1084 DIAGNOSTIC PERFORMANCE OF AN ANEUPLOIDY-BASED CLASSIFICATION OF BARRETT’S ESOPHAGUS TO IDENTIFY INDIVIDUALS WITH PREVALENT NEOPLASIA
Gastrointestinal Endoscopy · 2026-05-01
Sa1084 DIAGNOSTIC PERFORMANCE OF AN ANEUPLOIDY-BASED CLASSIFICATION OF BARRETT’S ESOPHAGUS TO IDENTIFY INDIVIDUALS WITH PREVALENT NEOPLASIA
Gastroenterology · 2026-05-01
A plasma-based DNA test for quantification of disease burden in acute myeloid leukemia patients undergoing bone marrow transplantation
Proceedings of the National Academy of Sciences · 2026-04-14
TRBC2-targeting antibody–drug conjugates for the treatment of T cell cancers
Nature Cancer · 2025-12-22 · 2 citations
Figure S1 from The Origin of Highly Elevated Cell-Free DNA in Healthy Individuals and Patients with Pancreatic, Colorectal, Lung, or Ovarian Cancer
2025-12-12
Figure S4 from The Origin of Highly Elevated Cell-Free DNA in Healthy Individuals and Patients with Pancreatic, Colorectal, Lung, or Ovarian Cancer
2025-12-12
Figure S8 from The Origin of Highly Elevated Cell-Free DNA in Healthy Individuals and Patients with Pancreatic, Colorectal, Lung, or Ovarian Cancer
2025-12-12
Supplementary Notes 1-5 from The Origin of Highly Elevated Cell-Free DNA in Healthy Individuals and Patients with Pancreatic, Colorectal, Lung, or Ovarian Cancer
2025-12-12
Figure S2 from The Origin of Highly Elevated Cell-Free DNA in Healthy Individuals and Patients with Pancreatic, Colorectal, Lung, or Ovarian Cancer
2025-12-12
Figure S3 from The Origin of Highly Elevated Cell-Free DNA in Healthy Individuals and Patients with Pancreatic, Colorectal, Lung, or Ovarian Cancer
2025-12-12
Figure S7 from The Origin of Highly Elevated Cell-Free DNA in Healthy Individuals and Patients with Pancreatic, Colorectal, Lung, or Ovarian Cancer
2025-12-12
Figure S9 from The Origin of Highly Elevated Cell-Free DNA in Healthy Individuals and Patients with Pancreatic, Colorectal, Lung, or Ovarian Cancer
2025-12-12
Figure S5 from The Origin of Highly Elevated Cell-Free DNA in Healthy Individuals and Patients with Pancreatic, Colorectal, Lung, or Ovarian Cancer
2025-12-12
Supplementary Tables S1 and S2 from The Origin of Highly Elevated Cell-Free DNA in Healthy Individuals and Patients with Pancreatic, Colorectal, Lung, or Ovarian Cancer
2025-12-12
Figure S6 from The Origin of Highly Elevated Cell-Free DNA in Healthy Individuals and Patients with Pancreatic, Colorectal, Lung, or Ovarian Cancer
2025-12-12
Figure S10 from The Origin of Highly Elevated Cell-Free DNA in Healthy Individuals and Patients with Pancreatic, Colorectal, Lung, or Ovarian Cancer
2025-12-12
Engineering immunotoxin-equipped effector cells and evaluation in primary human immune cellsPreprint
bioRxiv (Cold Spring Harbor Laboratory) · 2025-12-11 · 1 citations
Molecular Evidence of Multiorgan Damage in Patients with Immune-Related Adverse Events
New England Journal of Medicine · 2025-12-10 · 3 citations
A plasma-based test for the measurable residual disease informs the response to treatment in AML patients
Blood · 2025-11-03
Circulating tumor DNA-guided adjuvant therapy in locally advanced colon cancer: the randomized phase 2/3 DYNAMIC-III trial
Nature Medicine · 2025-10-20 · 40 citations

Open author page on OpenAlex →